selective short-acting ß1-antagonist, landiolol, has been reported to have a lesser effect on blood pressure compared to esmolol in animal models and in a clinical trial [15] [16] [17] . However, no consensus has been reached regarding the optimum dose or the mode and timing of delivery. Currently, landiolol is used only in Japan, but it is likely that it will soon be used worldwide. Prior to this, it is important to evaluate the efficacy of landiolol based on the Japanese experience. To achieve this goal, we conducted a systematic review of the effects of landiolol on haemodynamic alterations induced by LTI and the degree of hypotension and bradycardia produced by landiolol when co-administered with anaesthetics.
MeTHoDS

Literature search for trials
The study was performed as a systematic review in accordance with the recommendations of the QUOROM consensus statement 18 , and according to a protocol with specified outcomes, search strategies, inclusion criteria and statistical analyses. A search was undertaken in accordance with the cochrane collaboration recommendations to identify all published and unpublished randomised controlled trials of landiolol vs placebo in any language. MeDLINe, cochrane ceNTRAL and eMBASe were searched from their date of inception to Feburary 2009. The database of medical journals (Igaku-chuo Zasshi; the Japanese central Review of Medicine) produced by the Japan Medical Abstract Society was also searched; use of this database was essential for this review because landiolol is only available for clinical use in Japan. Search terms included variants of "landiolol", "intubation" and/or "laryngoscopy". Tangential electronic exploration of related articles and manual searches of bibliographies and surgical and anaesthesia journals were also performed. Full texts of the relevant articles were obtained. If the published data were incomplete, we contacted the corresponding author for verification or updates. If the study had been presented as an abstract, as well as an original article, data from the full report were used.
Inclusion criteria
Studies were included if they met all of the following criteria: 1) randomised allocation of patients to landiolol and placebo groups; 2) adult patients undergoing LTI; and 3) reporting of any of the four haemodynamic variables systolic blood pressure (SBP), diastolic blood pressure, mean blood pressure (MBP) and HR. It was also required that the studies contained baseline values and at least another two values of these variables: the first in the period between administration of landiolol or placebo and laryngoscopy, and the second within five minutes after endotracheal intubation.
Data extraction
We identified trials for inclusion in the study and extracted information on demographics, interventions (landiolol or placebo) and outcomes, including baseline values of variables (BP, HR), minimum values after administration of landiolol and maximum values following tracheal intubation. In addition, each trial was assigned a Jadad quality score, which evaluates randomisation, blinding and completeness of follow-up (maximum score, five) 19 . Briefly, if the study was described as randomised, one point was assigned and an additional point assigned if the randomisation process was judged to be appropriate, whereas if the randomisation was inappropriate (e.g. allocation by date of birth) the original point was lost. one point was also given if a study was described as blinded and an additional point was assigned if the blinding method was appropriate. Finally, one point was assigned if the number of and reasons for withdrawals and dropouts were described. Disagreements regarding the Jadad score were resolved by consensus. The sequence of administration of anaesthetic agents and landiolol, the ASA physical status of the patients, inclusion of opiates in the anaesthetic protocol, exclusion criteria and descriptions of adverse effects were also extracted from each study.
Data handling was performed according to the systematic review of esmolol and LTI conducted by Figueredo and garcia-Fuentes 10 . In short, the following data were calculated for each variable in each group of patients from each study: the percentage increase from the baseline value (BV) to the maximum observed value 
Statistical analysis
Meta-analysis was used for a given variable only when the variable was evaluated in two or more studies using the same dose or regimen for landiolol compared with placebo. Outcomes were analysed as continuous variables. Results are reported as the weighted mean difference and the 95% confidence interval (CI) of the changes in each haemodynamic variable between the treatment and placebo groups. Heterogeneity was explored using the Q-statistic, with P <0.10 suggesting significant heterogeneity between trials. In addition, the I-squared value was calculated to define the proportion of heterogeneity observed between trials that could be explained by chance. For each outcome, the Mantel-Haentzel (fixed effect) or DerSimonian and Laird (random effects) model was used when the Q-statistic suggested a lack of or a presence of heterogeneity, respectively. Statistical significance was defined as a two-tailed P<0.05, or a 95% CI that excluded values with no difference. Data were analysed using RevMan (v4.2, cochrane collaboration, 2004).
ReSULTS
A total of 85 citations were screened (six from EMBASE, 14 from MEDLINE, five from Cochrane CENTRAL and 60 from Igaku-Chuo Zasshi). Twenty-two trials were excluded because of duplicate references and 51 were excluded because they were non-clinical trials, on-going studies or abstracts that were subsequently published as full articles. A total of 12 trials 15, [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] were retrieved for in-depth consideration for inclusion in the review. However, five of these trials were subsequently excluded: three because of a missing placebo group 22, 27, 28 , one because of a duplicate publication 29 and one because of missing minimum values for variables after administration of landiolol 26 (for this study, we contacted the corresponding author by email to try to clarify the data). This left seven eligible trials with a total of 325 patients. one article 30 reported two studies, one of which was performed in hypertensive patients and was excluded from this analysis. The other study investigated the optimal timing for landiolol administration in normotensive patients, with the finding that four minutes before LTI was most effective. Thus, only data from this study for landiolol administration four minutes before LTI was used in the meta-analysis.
Of the seven trials, five used a continuous infusion regimen of 0.125 mg/kg/minute landiolol for one minute followed by 0.04 mg/kg/minute landiolol, whereas two used a 0.1 or 0.3 mg/kg bolus dose of landiolol. Patients who received alternative therapeutic agents for comparison with landiolol (n=55) were omitted to simplify the meta-analysis. The characteristics of the trials included in the meta-analysis are shown in Table 1 . HR was evaluated in all studies, MBP in four studies and SBP in three studies. All studies had a Jadad score ≥3 and none included concomitant use of opiates during induction of anaesthesia.
The percentage changes relative to baseline are shown in Table 2 . The two studies of bolus administration of landiolol used MBP and SBP, respectively, for blood pressure evaluation. Therefore, the respective sets of values for MBP and SBP were derived from a single study. Meta-analysis of a bolus dose was performed only for evaluation HR=heart rate, MBP=mean blood pressure, SBP=systolic blood pressure, %Mini=percentage decrease from the baseline value to the minimum value before laryngoscopy and tracheal intubation, %Max=percentage increase from the baseline value to the maximum value after laryngoscopy and tracheal intubation.
of the HR response before and after LTI for a 0.1 mg/kg bolus of landiolol. The HR decrease before LTI and increase after LTI were unaffected by 0.1 mg/kg of landiolol (Figures 1 and 2) . The blood pressure decrease before LTI and increase after LTI did not appear to be affected by any bolus dose of landiolol.
Meta-analysis was performed for continuous infusion based on five trials. Of these, three included evaluation of MBP and two used SBP. The metaanalyses for HR, MBP and SBP are presented in Figures 3 to 8 . The increases in HR and blood pressure following LTI were effectively suppressed by continuous infusion of landiolol. with this administration regimen, HR and SBP were significantly decreased before LTI, but did not appear to be adversely depressed (-3.5% and -12% reductions from baseline, respectively; Table 2 ).
The MBP increase after LTI was also suppressed by landiolol, but MBP before LTI was not affected by landiolol.
Regarding adverse effects induced by landiolol, the incidence of bradycardia or hypotension was not increased compared to placebo in any study.
DIScUSSIoN
The results of this systematic review demonstrate that increases in HR and blood pressure following LTI are effectively suppressed by continuous infusion of landiolol and that this regimen does not adversely depress HR and blood pressure before LTI. Bolus administration of landiolol may be effective for preventing haemodynamic response to LTI, but it is difficult to evaluate the efficacy because of the small number of studies.
Landiolol is an ultra-short acting ß-antagonist with a half-life of three minutes that is eight times more cardioselective than esmolol. It is recommended that landiolol is administered by continuous infusion due to its ultra-short acting properties [31] [32] [33] . The continuous dose regimen of landiolol used in the series of studies for LTI appears to have been based on the dosage for treatment of perioperative supraventricular tachycardia and the first use of landiolol for prevention of tachycardia induced by tracheal intubation, as reported by Hasuo et al 20, 34 .
It is important to avoid tachycardia without reducing blood pressure to maintain coronary perfusion 11 . The HR response following LTI was effectively suppressed with continuous landiolol administration (a HR decrease from 42 to 11%); however, blood pressure after LTI did not appear to be adversely depressed from baseline (decreases of MBP from 39 to 29% and SBP from 16 to -0.3%). Landiolol has been reported to have a slightly more potent negative chronotropic action than esmolol, with a significantly lower effect on blood pressure and a less potent negative inotropic effect in an animal model 17, 35 . Of the studies in this metaanalysis, only one compared the haemodynamics of landiolol and esmolol 25 . No differences between landiolol and esmolol were found and both suppressed haemodynamic responses to LTI compared to placebo 25 without adverse depression of blood pressure. Therefore, landiolol and esmolol may have a similar negative chronotropic action and minor effects on blood pressure clinically, in contrast to findings in experimental models.
There is a natural depression of haemodynamics after induction of anaesthesia but before LTI, and it is of concern that continuous landiolol administration may cause further haemodynamic depression during this period. HR and blood pressure were significantly decreased (HR from 4.9 to -3.5%, MBP from -13 to -16%, and SBP from -3 to -12%); however, these decreases are probably clinically negligible. Therefore, continuous landiolol administration does not seem to have a synergistic depressive effect on haemodynamics in combination with anaesthetic agents.
As mentioned above, two studies evaluated the efficacy of a bolus dose of landiolol on haemodynamic responses to LTI 15, 30 . Yamazaki et al investigated the optimal timing of bolus administration of 0.1 mg/kg landiolol using time points of just before and two and four minutes before LTI 15 , and found that administration four minutes before LTI was most effective in preventing tachycardia following LTI. In contrast, Sugiura et al found that the effect of a bolus of 0.1 mg/kg landiolol on the haemodynamic response following LTI did not differ from placebo 30 . However, the interval (90 seconds) between landiolol administration and LTI may have been too short to allow an effect, and with this interval a dose of 0.3 mg/kg of landiolol was required for attenuation of the haemodynamic response to LTI compared with placebo 30 . Yamazaki et al also investigated the effects of landiolol in hypertensive patients, and found that a dose of 0.2 mg/kg (rather than 0.1 mg/kg) was needed to prevent tachycardia after LTI 15 . Interestingly, bolus administration of landiolol at any dose or time did not show a significant effect on blood pressure compared with placebo in either study. However, further studies of the optimal dose and timing are needed for assessment of the efficacy of bolus administration of landiolol for reducing haemodynamic responses to LTI.
In conclusion, this systematic review demonstrated that administration of landiolol for 0.125 mg/kg/minute for one minute followed by infusion at 0.04 mg/kg/minute effectively and safely suppresses the increases in HR and blood pressure following LTI. A bolus regimen of landiolol might also be effective for suppressing the haemodynamic response to LTI, but further studies are needed to establish the optimal dose and timing and to evaluate the efficacy of a bolus dose.
